Results 11 to 20 of about 345,959 (307)

Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study

Frontiers in Oncology, 2023
BackgroundAlthough several clinical studies have laid the foundation for the adjuvant application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), some questions remain unresolved.
Jun-Feng Liu, Xu-Sheng Sun, Jin-Huan Yin, Xi-E Xu   +3 more
doaj   +1 more source

Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma

Cancer Medicine, 2022
Objective Currently, there is no standard adjuvant treatment protocol for localized uterine leiomyosarcoma (uLMS) as clinical trials to address this question have been retrospective, underpowered, or undermined by slow accrual rates.
Jomjit Chantharasamee, Karlton Wong, Pasathorn Potivongsajarn, Amir Qorbani, Neda Motamed, Sandra Brackert, Joshua Cohen, Bartosz Chmielowski, Anusha Kalbasi, Jianyu Rao, Scott Nelson, Arun Singh   +11 more
doaj   +1 more source

Postoperative adjuvant therapy [PDF]

Journal of Hepato-Biliary-Pancreatic Sciences, 2011
AbstractAfter a lengthy search for an effective treatment for resected pancreatic cancer, evidence accumulated in the past 10 years shows that adjuvant chemotherapy is firmly established as offering a modest but real improvement in overall survival.
Tomoo, Kosuge, Yoshihiro, Sakamoto, Hideki, Ueno   +2 more
openaire   +2 more sources

Augmented Features Synergize Radiomics in Post-Operative Survival Prediction and Adjuvant Therapy Recommendation for Non-Small Cell Lung Cancer

Frontiers in Oncology, 2022
BackgroundOwing to the cytotoxic effect, it is challenging for clinicians to decide whether post-operative adjuvant therapy is appropriate for a non-small cell lung cancer (NSCLC) patient. Radiomics has proven its promising ability in predicting survival
Lawrence Wing-Chi Chan, Tong Ding, Huiling Shao, Mohan Huang, William Fuk-Yuen Hui, William Chi-Shing Cho, Sze-Chuen Cesar Wong, Ka Wai Tong, Keith Wan-Hang Chiu, Luyu Huang, Luyu Huang, Haiyu Zhou, Haiyu Zhou   +12 more
doaj   +1 more source

Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate‐risk group

Cancer Medicine, 2023
Background The efficacy of adjuvant therapy for patients with cervical cancer with intermediate risk (CC‐IR) remains controversial. We examined the impact of adjuvant therapy on survival outcomes in patients with CC‐IR and evaluated the heterogeneous ...
Ayumi Taguchi, Kosuke Kato, Konan Hara, Akiko Furusawa, Yujiro Nakajima, Chihiro Ishizawa, Michihiro Tanikawa, Kenbun Sone, Mayuyo Mori, Muneaki Shimada, Aikou Okamoto, Munetaka Takekuma   +11 more
doaj   +1 more source

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX

Frontiers in Oncology, 2022
BackgroundThe complete resection rate of pancreatic cancer has increased because of the advent of efficacious first-line treatments for unresectable pancreatic cancer.
Jin Ho Choi, Min Kyu Kim, Sang Hyub Lee, Jin Woo Park, Namyoung Park, In Rae Cho, Ji Kon Ryu, Yong-Tae Kim, Jin-Young Jang, Wooil Kwon, Hongbeom Kim, Woo Hyun Paik   +11 more
doaj   +1 more source

Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma. [PDF]

PLoS ONE, 2018
OBJECTIVE:The role of adjuvant therapy in small bowel adenocarcinoma (SBA), a rare malignancy with a poor prognosis, is controversial. The purpose of this article is to investigate the impact of adjuvant therapy on the survival of patients with SBA in a ...
Xiaojian Ye, Guoqiang Zhang, Haibin Chen, Yong Li   +3 more
doaj   +1 more source

Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers [PDF]

Zhongguo aizheng zazhi, 2022
Background and purpose: Anti-programmed death-1 (anti-PD-1) adjuvant therapy and targeted therapy have resulted in longer recurrence-free survival (RFS) for malignant melanoma patients in clinical trials.
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong
doaj   +1 more source

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials

BMC Cancer, 2023
Purpose To determine the role and rational application of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant non-small-cell lung cancer (NSCLC).
Shu-Ling Zhang, Xiao-Fang Yi, Le-Tian Huang, Li Sun, Jie-Tao Ma, Cheng-Bo Han   +5 more
doaj   +1 more source

Perioperative chemotherapy in colorectal cancer with peritoneal metastases: A global propensity score matched studyResearch in context

EClinicalMedicine, 2023
Summary: Background: There is a paucity of studies evaluating perioperative systemic chemotherapy in conjunction with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer peritoneal ...
Peter H. Cashin, Jesus Esquivel, Stein G. Larsen, Winston Liauw, Nayef A. Alzahrani, David L. Morris, Vahan Kepenekian, Isabelle Sourrouille, Frédéric Dumont, Jean-Jacques Tuech, Cécilia Ceribelli, Beranger Doussot, Olivia Sgarbura, Francois Quenet, Olivier Glehen, Oliver M. Fisher   +15 more
doaj   +1 more source